Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
Add filters








Type of study
Language
Year range
1.
Middle East Journal of Emergency Medicine [The]. 2006; 6 (2): 36-38
in English | IMEMR | ID: emr-79697

ABSTRACT

Esophageal ulceration occasionally occurs in patients taking doxycycline capsules or tablets. We report two patients who develop acute esophageal ulceration after ingestion of doxycycline capsules for Acne vulgaris. Despite extensive investigation, no evidence of other causes was found. The ulcers are postulated to result from close contact between the capsules and the esophageal mucosa. We show the endoscopic image of the lesion, symptomatology, diagnosis, treatment, and prevention of doxycycline-induced esophageal lesions


Subject(s)
Humans , Male , Female , Doxycycline/adverse effects , Peptic Ulcer/chemically induced , Signs and Symptoms, Digestive , Esophagitis/pathology
2.
Saudi Medical Journal. 2003; 24 (4): 347-351
in English | IMEMR | ID: emr-64564

ABSTRACT

The aim of this study is to evaluate the response rate of hyperthyroidism to radioactive iodine [RAI] treatment, optimum effective dose, effect of pretreatment with thyrostatic medications, etiology, ophthalmopathy, mortality and cancer incidence post RAI treatment. Retrospective study analysis of 360 patients records who received RAI treatment [dose 5-15 mCi] for hyperthyroidism in Hamad Medical Corporation, Qatar between 1984-1999, treated and analyzed. Follow-up data was available in 215 patients, with a follow-up range of 2-10 years, of these 84 were males and 131 were females, with an age range of 12-74 years. Eighty% were toxic diffuse goiter, 13.5% were toxic multinodular goiter and 6.5% were toxic single nodule. Eighty-seven% had been pre-treated with anti-thyroid medications. Free thyroxine4, and thyroid stimulating hormone were recorded at diagnosis; 6 months, one year and yearly post RAI treatment. The incidence of hypothyroidism was 55.8% at 6 months and 67.9% at one year. There was no significant difference in the response rate to different doses of RAI treatment groups [50-59%, p=0.46]. The response rate was significantly higher in the group without pre-treatment with anti-thyroid medications [95% versus 80.9%, p<0.0001] and 27.4% of our patients had ophthalmopathy. There was no significant worsening or new development of ophthalmopathy post RAI treatment. Three of our patients developed cancer: one with colonic, one with breast and one with acute leukemia. The mortality rate according to the age group was linear in the positive direction of age and the highest was 74-year-old [10.5 per 10,0000 population]. Radioactive iodine treatment is an effective modality for definitive treatment of hyperthyroidism with long-term cure approaching 80%. Response rate was not related to gender, etiology or RAI dosage. Pre-treatment with anti-thyroid medication reduces the response rate. Radioactive iodine treatment has no significant influence on ophthalmopathy, mortality or thyroid cancer


Subject(s)
Humans , Male , Female , Iodine Radioisotopes , Iodine Radioisotopes/administration & dosage , Retrospective Studies , Treatment Outcome
SELECTION OF CITATIONS
SEARCH DETAIL